Colossal targets artificial womb births within two years

The surrogate bottleneck for de-extinction is about to break.

On Moonshots with Peter Diamandis, Colossal Biosciences CEO Ben Lamm announced that his firm expects to gestate and birth mammals entirely ex utero within 24 months. The shift to synthetic wombs eliminates the reliance on live surrogate mothers. For ambitions like resurrecting the woolly mammoth, which demand birthing thousands of animals to establish self-sustaining herds, using living surrogates was mathematically unfeasible.

The rapid timeline relies on dramatic improvements in multiplex gene editing. Colossal routinely executes over 300 base edits per delivery and is currently testing 1,000 simultaneous edits in the lab. Lamm projected that full organism design software - where scientists prompt specific physical traits directly into a synthetic genome - will arrive within the decade.

Following recent advances in cellular manufacturing like those highlighted in late September by Martine Rothblatt's organ-based reversal targets, synthetic biology is shifting from medical workarounds to foundational rewriting. Yet Lamm drew a hard boundary between animal conservation and human engineering. Colossal explicitly ruled out using its genome editing tools on humans, citing frozen regulatory timelines under the FDA and massive ethical liabilities.

Instead, the company is treating synthetic biology alongside high-performance compute and machine learning as a dual-use technical stack. Lamm warned that combining advanced gene editing with high-performance AI models creates capabilities more powerful than any historical weapon system. As large-scale DNA synthesis replaces multiplex editing as the primary method for writing living code, society remains largely unprepared for the resulting biosecurity hazards.

Standard artificial intelligence infrastructure also falls short when applied to genetic sequence design. Lamm argued that foundational language models cannot build a functional organism from a raw genome alone. Instead of larger model architectures, mapping genetic code to physical traits requires massive, proprietary evolutionary datasets.

To assemble those datasets, Colossal launched a global bio vault initiative to sequence endangered species in localized archives before biodiversity loss claims them. The company also spun out Astromech, a specialized venture that feeds comparative genomic data into foundational models to bridge the gap between digital sequencing and living biology.

The push into ex utero gestation transforms de-extinction from an academic curiosity into an industrial assembly line.